Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02184442 · ClinicalTrials.gov registry record · NA
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B
A NA study, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- NA
- Development phase
- 560
- Enrollment target
NCT02184442: Completed NA study, sponsored by Edwards Lifesciences.
NCT02184442 is a NA study that has completed, run by Edwards Lifesciences. The registered enrollment target is 560 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02184442, a NA study, has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 560 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of the SAPIEN XT™ THV with the associated delivery system for inoperable patients with severe symptomatic native aortic stenosis.
Primary Outcome
All-Cause Mortality and/or Major Stroke and/or Rehospitalization at 1 Year
Interventions
- DEVICE TAVR Implantation with SAPIEN XT
- DEVICE TAVR Implantation with SAPIEN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2011-03-09 |
| Est. Completion | 2017-05-30 |
| Phase | NA |
What the finished NCT02184442 record still lists
NCT02184442 is an interventional study that assigns participants to a tested intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which TAVR Implantation with SAPIEN XT is the first listed.
NCT02184442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02184442 about?
NCT02184442 is a clinical study titled "The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B". The purpose of this study is to determine the safety and effectiveness of the SAPIEN XT™ THV with the associated delivery system for inoperable patients with severe symptomatic native aortic stenosis.
What is the current status of trial NCT02184442?
This trial is currently completed. It is a NA study. The enrollment target is 560 participants. The study started on 2011-03-09. Estimated completion is 2017-05-30.
What interventions are being tested in trial NCT02184442?
The interventions under investigation include: TAVR Implantation with SAPIEN XT (DEVICE), TAVR Implantation with SAPIEN (DEVICE).
Who is sponsoring clinical trial NCT02184442?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02184442's enrollment target sits among peer trials
560 181st of 2000 higher than 1,818 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI